These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29662194)

  • 1. An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo.
    Tomoshige K; Guo M; Tsuchiya T; Fukazawa T; Fink-Baldauf IM; Stuart WD; Naomoto Y; Nagayasu T; Maeda Y
    Oncogene; 2018 Jul; 37(28):3894-3908. PubMed ID: 29662194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.
    Ambrogio C; Barbacid M; Santamaría D
    Oncogene; 2017 Apr; 36(16):2309-2318. PubMed ID: 27775074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.
    Takamochi K; Mogushi K; Kawaji H; Imashimizu K; Fukui M; Oh S; Itoh M; Hayashizaki Y; Ko W; Akeboshi M; Suzuki K
    PLoS One; 2017; 12(4):e0175622. PubMed ID: 28422979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung.
    Maeda Y; Tsuchiya T; Hao H; Tompkins DH; Xu Y; Mucenski ML; Du L; Keiser AR; Fukazawa T; Naomoto Y; Nagayasu T; Whitsett JA
    J Clin Invest; 2012 Dec; 122(12):4388-400. PubMed ID: 23143308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma].
    Zhang H; Yang X; Qin N; Li X; Yang H; Nong J; Lv J; Wu Y; Zhang Q; Zhang X; Wang J; Zhou L; Zhang S
    Zhongguo Fei Ai Za Zhi; 2015 Nov; 18(11):686-90. PubMed ID: 26582224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
    Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y
    Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
    Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
    Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS.
    Guha U; Chaerkady R; Marimuthu A; Patterson AS; Kashyap MK; Harsha HC; Sato M; Bader JS; Lash AE; Minna JD; Pandey A; Varmus HE
    Proc Natl Acad Sci U S A; 2008 Sep; 105(37):14112-7. PubMed ID: 18776048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.
    Unni AM; Lockwood WW; Zejnullahu K; Lee-Lin SQ; Varmus H
    Elife; 2015 Jun; 4():e06907. PubMed ID: 26047463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
    Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
    Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone Metastases and the EGFR and KRAS Mutation Status in Lung Adenocarcinoma--The Results of Three Year Retrospective Analysis.
    Bittner N; Balikó Z; Sárosi V; László T; Tóth E; Kásler M; Géczi L
    Pathol Oncol Res; 2015 Sep; 21(4):1217-21. PubMed ID: 26055897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IκB Kinase α Is Required for Development and Progression of
    Vreka M; Lilis I; Papageorgopoulou M; Giotopoulou GA; Lianou M; Giopanou I; Kanellakis NI; Spella M; Agalioti T; Armenis V; Goldmann T; Marwitz S; Yull FE; Blackwell TS; Pasparakis M; Marazioti A; Stathopoulos GT
    Cancer Res; 2018 Jun; 78(11):2939-2951. PubMed ID: 29588349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
    Eng J; Woo KM; Sima CS; Plodkowski A; Hellmann MD; Chaft JE; Kris MG; Arcila ME; Ladanyi M; Drilon A
    J Thorac Oncol; 2015 Dec; 10(12):1713-9. PubMed ID: 26334752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
    Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
    Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition between morule-like and solid components may occur in solid-predominant adenocarcinoma of the lung: report of 2 cases with EGFR and KRAS mutations.
    Tajima S; Koda K
    Int J Clin Exp Pathol; 2015; 8(6):7475-81. PubMed ID: 26261656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.
    Akbay EA; Koyama S; Liu Y; Dries R; Bufe LE; Silkes M; Alam MM; Magee DM; Jones R; Jinushi M; Kulkarni M; Carretero J; Wang X; Warner-Hatten T; Cavanaugh JD; Osa A; Kumanogoh A; Freeman GJ; Awad MM; Christiani DC; Bueno R; Hammerman PS; Dranoff G; Wong KK
    J Thorac Oncol; 2017 Aug; 12(8):1268-1279. PubMed ID: 28483607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas.
    Simon E; Bick T; Sarji S; Shentzer T; Prinz E; Yehiam L; Sabo E; Ben-Izhak O; Hershkovitz D
    Oncotarget; 2017 Jul; 8(28):45736-45749. PubMed ID: 28501852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
    Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
    Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
    Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
    Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.